RightFit
RecruitingNot applicable

A Study Evaluating a New Radiation Treatment Workflow (NGDS)

A ProSPEctivE Study of NGDS DMAT Workflow Feasibility

Who can join

As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.

Age
21 Years and older
Sex
All sexes
Healthy volunteers
Not accepted
Compensation
Not stated

Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.

What to expect

No one can promise a trial will help you personally — that is what the research is trying to find out.

What participation involves

Not stated in the study description — ask the study team about visits and procedures.

Compensation
Not stated
  • Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
  • Participants are monitored closely by the research team throughout the study.
  • Some participants may receive access to an investigational treatment, which is still being studied.
  • Your participation helps researchers learn whether this approach could help future patients.

About this study

The purpose of this research is to evaluate the "Next Generation Delivery System" (NGDS) and determine if this machine will be more efficient at delivering radiation in shorter treatment time and better patient tolerance, with less breath holding.

Compensation is read from the study's own description and may be missing — always confirm with the study team.

Eligibility

Official eligibility criteria

Inclusion Criteria: 1. Target lesions in the thorax or upper abdomen 2. Planned to undergo SBRT radiation treatment delivered on a conventional "C-arm" or ring gantry CBCT guided linear accelerator under breath hold conditions 3. ECOG performance status 0-1 4. At least 21 years of age 5. Able to sign informed consent Exclusion Criteria: 1. Participants enrolled in another clinical investigation the investigator believes to be in conflict with this clinical investigation. 2. Participants with any other medical condition or laboratory value that would, at the discretion of the investigator, preclude the patient from participation in this clinical investigation.

Study sites (2)

MO

  • Siteman Cancer Center Washington University · St Louis, MO 63108Pamela Samson · Principal investigatorMore trials in St Louis

OH